Navigation Links
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Date:12/17/2007

nts each. This is within the range expected to occur with the use of anthracycline based chemotherapy alone.

Following the completion of the accrual of Avastin adjuvant colon cancer trials and now confirmation of the safety of Avastin in the adjuvant breast cancer setting, the phase III adjuvant breast cancer programme is already recruiting patients. The large adjuvant programme consists of 2 trials in HER- 2 negative breast cancer patients:

-- The E5103 study is set to include 4,950 patients and will compare

Avastin with the addition of an anthracycline-containing chemotherapy

course versus anthracycline-containing chemotherapy alone.

-- The BEATRICE study will investigate Avastin in combination with

standard chemotherapies compared to chemotherapies alone in 2,530

planned patients who are not candidates for hormonal therapy.

In addition, Avastin is being investigated in HER-2 positive breast cancer patients post surgery via the BETH trial. This study will investigate the

addition of Avastin to Herceptin (trastuzumab) in combination with established chemotherapy regimen.

Worldwide, breast cancer is the leading cause of cancer death in women under the age of 55. Each year there are more than one million diagnoses and more than 400,000 deaths from breast cancer (2).

About E2104

E2104 is a phase II study designed to evaluate the safety and feasibility of incorporating Avastin into an anthracycline containing adjuvant therapy regimen. The study included 226 women with lymph node positive breast cancer who have had already undergone surgical removal (mastectomy) of the lesion and lymph node dissection. The study was sponsored by the National Cancer Institute (NCI), part of the US National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG). Patients were sequentially assigned to
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
2. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  In part four of ... hospital pharmacy as a strategic asset, Mary Baxter, ... for Cardinal Health,s Innovation Delivery Solutions business, discusses how ... both hospitals and patients. "Every hospital pharmacist ... of their job in a value-based healthcare world," Baxter ...
(Date:8/29/2014)... DUBLIN , August 29, 2014 ... management and collaboration software has announced a major new ... services, founded by renowned pathology expert, Dr. Marius ... advance of the 26th European Congress of Pathology which ... in the ExCeL Arena, London ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: North America Aesthetic Lasers and ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North America ... 2020 Summary GlobalData,s new report, "North ... to 2020", provides key market data on the ...
Breaking Medicine Technology:Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... May 6 Vanda Pharmaceuticals Inc. (Nasdaq: ... Drug Administration (FDA) has granted marketing approval of Fanapt(TM) ... schizophrenia. The approval was supported by two placebo-controlled Phase ... control in patients with schizophrenia, as well as safety ...
... provide important insight for physicians in treating heart attack ... BSX ) today welcomed the publication of ... issue of the New England Journal of Medicine. ... Foundation with research grant support from Boston Scientific and ...
Cached Medicine Technology:FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 2FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 3FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 4FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 5FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 6FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 7Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 2Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 3Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 4Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 5
(Date:8/30/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:8/30/2014)... One of the most recent dietary trends ... diet. Originally meant for sufferers of gluten intolerance and celiac ... who are looking to get healthier by simply consuming foods ... kind of information erroneous, it also exposes those same consumers ... a drastic change in their food consumption habits. ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The new review ... program was created by Karen Brimeyer, who wanted to make ... , This guide is now easy to find in ... download. In this guide, the author of the new method ... , Daily Gossip writes in its review that the ...
(Date:8/30/2014)... 30, 2014 August 28th, 2014: ... in our society and the toll that takes on ... vital that continuing education for physical therapists addresses this ... physical therapists help others, Hands-On Seminars is offering discounts ... , Three learning styles are available to fit the ...
(Date:8/30/2014)... NJ (PRWEB) August 30, 2014 Ms. Meriwether’s ... her. She certainly has an impressive resume to boost. ... Miss USA in 2012. However, she’s also a two ... Grad student. Nana trained for the 2008 Olympics and ... Miss USA website, “This six-foot beauty from Potomac, Maryland is ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:NJ Top Dentists Announces Cover Model for the Healthy Living: Top Dentists Issue 2
... Ind., April 14 Conseco, Inc. (NYSE:,CNO) ... promoted to vice president,enterprise risk management, reporting ... actuary. Mr. Bischof is responsible for overseeing ... conjunction,with Conseco,s Enterprise Risk Management Committee., ...
... April 14 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ), ... and audio web cast on Wednesday, April 30, 2008,at ... release of its,financial results for the first quarter ended ... 6:30 a.m. ET on Wednesday,April 30, 2008., To ...
... male hormone in the morning made more money , , MONDAY, ... finds that financial traders who wake up with high levels ... that day, probably because they feel more daring. , ... stress hormone cortisol tend to be more cautious. , "We ...
... The Pharmaceutical Care,Management Association (PCMA) issued the ... New York Times on skyrocketing biotech prices:, ... and will,spend $100 billion within a few years. ... because they don,t face generic competition once their,patents ...
... Cogdell Spencer,Inc. (NYSE: CSA ) announced today that ... on Monday, May 5, 2008. Cogdell Spencer,Inc. invites you ... May 6, 2008 at 10:00 a.m. (Eastern Time). The ... or (412) 858-4600,(international). In addition, the conference call can ...
... that hypertension should still be treated , , MONDAY, April ... are less likely to have headaches than those with ... one headache expert cautions that the new research does ... or stop taking their blood pressure medications. , The ...
Cached Medicine News:Health News:Testosterone Levels Among Financial Traders Affect Performance 2Health News:Testosterone Levels Among Financial Traders Affect Performance 3Health News:Cogdell Spencer Inc. Announces First Quarter Earnings Release and Conference Call Notice 2Health News:High Blood Pressure May Be Buffer Against Headaches 2Health News:High Blood Pressure May Be Buffer Against Headaches 3
... The Professional Gold Package ... your laboratory. The package includes ... and automated system, starter package ... v-block adapter, specimen mounts 1/2" ...
... provides a versatile means of sectioning fresh ... The 1000 employs a vibrating blade principle ... The creation of artifacts, the alteration ... and other deleterious effects inherent in freezing ...
... The NEW Vibratome 3000 Plus Sectioning System ... or fixed, animal, or plant tissues. ... which allows sectioning without freezing or embedding. ... of morphology, the destruction of enzyme activities, ...
... 3000 Deluxe Sectioning System provides a versatile ... or plant tissues. The 3000 employs ... without freezing or embedding. The creation ... destruction of enzyme activities, and other deleterious ...
Medicine Products: